Evommune, Nektar assets join list of recent successes in atopic derm

The week’s two biggest movers on clinical readouts are both developing atopic dermatitis candidates.

Shares of Evommune Inc. (NYSE:EVMN) rose 71% , lifting its market cap above $900 million, after the company announced Tuesday that its IL-18 fusion protein, EVO301, led to significant reductions in Eczema Area and Severity Index (EASI) scores over 4, 8, and 12 weeks, versus placebo, in a Phase II study. ...